摘要
食管癌是严重威胁人类健康的恶性肿瘤之一,同步放、化疗是治疗局部进展期食管癌的标准模式,但食管癌患者放、化疗后仍有复发早和预后差等特点。表皮生长因子受体(epithelial growth factor receptor,EGFR)抑制剂西妥昔单抗联合放疗对局部进展期头颈鳞癌的治疗获得了成功。本文根据西妥昔单抗在食管癌二线治疗、一线治疗及新辅助治疗中的应用情况,对西妥昔单抗治疗食管癌的安全性及疗效进行简要综述,指出西妥昔单抗联合同步放、化疗治疗局部晚期食管癌具有良好的耐受性和近期疗效,尤其是在新辅助治疗中的疗效令人振奋,值得为此开展多中心Ⅲ期临床研究。
Esophageal cancer （EC） is one of the malignant tumours which has a serious threat to human health. Although, concurrent radiochemotherapy is the standard treatment mode of locally advanced esophageal cancer （LAEC）, the early recurrence is still common, and the prognosis is poor. Epithelial growth factor receptor （EGFR） inhibitor cetuximab （a monoclonal antibody） combined with radiotherapy is effecive in the treatment of locally advanced head and neck squamous cell carcinoma. This review focuses on the efficacy and safety of cetuximab in second-line and first-line therapies as well as neoadjuvant therapy in the treatment of LAEC, and points out that cetuximab combined with chemoradiation therapy displays a good tolerance and a satisfactory short-term effect, especially in neoadjuvant therapy. A multicenter phase Ⅲ clinical trial of cetuximab plus chemoradiation in neoadjuvant therapy for patients with LAEC needs to be carried out.
出处
《肿瘤》
CAS
CSCD
北大核心
2014年第5期470-476,共7页
Tumor
基金
上海市卫生局科研课题(编号:2008150)
关键词
食管肿瘤
综合疗法
受体
表皮生长因子
西妥昔单抗
Esophageal neoplasms
Combined modality therapy
Receptor, epidermal growth factor
Cetuximab
作者简介
Correspondence to：叶明 E-mail： renjiye ming@gmail.com
